Sirt1 Activity in PBMCs as a Biomarker of Different Heart Failure Phenotypes.
Valeria ContiGraziamaria CorbiMaria Vincenza PolitoMichele CiccarelliValentina ManzoMartina TorsielloEmanuela De BellisFederica D'AuriaGennaro VitulanoFederico PiscioneAlbino CarrizzoPaola Di PietroCarmine VecchioneNicola FerraraFilippelli AmeliaPublished in: Biomolecules (2020)
Heart Failure (HF) is a syndrome, which implies the existence of different phenotypes. The new categorization includes patients with preserved ejection fraction (HFpEF), mid-range EF (HFmrEF), and reduced EF (HFrEF) but the molecular mechanisms involved in these HF phenotypes have not yet been exhaustively investigated. Sirt1 plays a crucial role in biological processes strongly related to HF. This study aimed to evaluate whether Sirt1 activity was correlated with EF and other parameters in HFpEF, HFmrEF, and HFrEF. Seventy patients, HFpEF (n = 23), HFmrEF (n = 23) and HFrEF (n = 24), were enrolled at the Cardiology Unit of the University Hospital of Salerno. Sirt1 activity was measured in peripheral blood mononuclear cells (PBMCs). Angiotensin-Converting Enzyme 2 (ACE2) activity, Tumor Necrosis Factor-alpha (TNF-α) and Brain Natriuretic Peptide (BNP) levels were quantified in plasma. HFpEF showed lower Sirt1 and ACE2 activities than both HFmrEF and HFrEF (p < 0.0001), without difference compared to No HF controls. In HFmrEF and HFrEF a very strong correlation was found between Sirt1 activity and EF (r2 = 0.899 and r2 = 0.909, respectively), and between ACE2 activity and Sirt1 (r2 = 0.801 and r2 = 0.802, respectively). HFrEF showed the highest TNF-α levels without reaching statistical significance. Significant differences in BNP were found among the groups, with the highest levels in the HFrEF. Determining Sirt1 activity in PBMCs is useful to distinguish the HF patients' phenotypes from each other, especially HFmrEF/HFrEF from HFpEF.
Keyphrases
- ejection fraction
- heart failure
- angiotensin converting enzyme
- oxidative stress
- ischemia reperfusion injury
- end stage renal disease
- angiotensin ii
- rheumatoid arthritis
- acute heart failure
- aortic stenosis
- peritoneal dialysis
- left ventricular
- acute kidney injury
- multiple sclerosis
- mass spectrometry
- subarachnoid hemorrhage
- resting state
- brain injury
- patient reported outcomes
- blood brain barrier
- cerebral ischemia
- high speed